Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 step » _ step (Expand Search), a step (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 step » _ step (Expand Search), a step (Expand Search)
-
1401
-
1402
<i>Ext1</i> mutant lungs exhibit a decrease in SHH-FGF10 signaling.
Published 2017“…<p>(A) qPCR analysis of key components of FGF signaling pathway in lungs from E14.5. …”
-
1403
-
1404
-
1405
-
1406
-
1407
-
1408
-
1409
-
1410
-
1411
List of Included studies.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
1412
The search strategy in three databases.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
1413
NIH score.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
1414
List of excluded studies.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
1415
-
1416
-
1417
-
1418
Nilotinib decreases HEI-193 cell viability in a time-, dose-, and growth condition- dependent manner.
Published 2013“…(B) HEI-193 grown in PDGF media were treated with 0, 3, 5, 10 or 20 µM nilotinib up to 5 days. Trypan blue viability assay shows decreased number of viable cells at 5 days in 3 µM nilotinib, compared to vehicle shown, mean and SD of six technical replicates. …”
-
1419
-
1420